The 36-month beta value for AKRO is at -0.30. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKRO is 57.80M, and currently, shorts hold a 14.16% of that float. The average trading volume for AKRO on May 07, 2024 was 1.39M shares.
AKRO) stock’s latest price update
Akero Therapeutics Inc (NASDAQ: AKRO) has experienced a rise in its stock price by 12.46 compared to its previous closing price of 19.66. However, the company has seen a gain of 12.69% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-05 that Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
AKRO’s Market Performance
Akero Therapeutics Inc (AKRO) has experienced a 12.69% rise in stock performance for the past week, with a -4.78% drop in the past month, and a 9.24% rise in the past quarter. The volatility ratio for the week is 6.26%, and the volatility levels for the past 30 days are at 5.11% for AKRO. The simple moving average for the past 20 days is 5.57% for AKRO’s stock, with a -21.57% simple moving average for the past 200 days.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Neutral.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $30 based on the research report published on April 22, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $69. The rating they have provided for AKRO stocks is “Overweight” according to the report published on September 19th, 2023.
UBS gave a rating of “Buy” to AKRO, setting the target price at $83 in the report published on August 28th of the previous year.
AKRO Trading at -9.07% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.13% of loss for the given period.
Volatility was left at 5.11%, however, over the last 30 days, the volatility rate increased by 6.26%, as shares sank -4.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.75% lower at present.
During the last 5 trading sessions, AKRO rose by +12.69%, which changed the moving average for the period of 200-days by -49.98% in comparison to the 20-day moving average, which settled at $20.89. In addition, Akero Therapeutics Inc saw -5.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Young Jonathan, who sale 5,000 shares at the price of $20.15 back on May 01 ’24. After this action, Young Jonathan now owns 258,306 shares of Akero Therapeutics Inc, valued at $100,750 using the latest closing price.
Young Jonathan, the Chief Operating Officer of Akero Therapeutics Inc, sale 5,000 shares at $24.38 during a trade that took place back on Apr 01 ’24, which means that Young Jonathan is holding 263,306 shares at $121,913 based on the most recent closing price.
Stock Fundamentals for AKRO
Current profitability levels for the company are sitting at:
- -608.7 for the present operating margin
- 0.49 for the gross margin
The net margin for Akero Therapeutics Inc stands at -525.68. The total capital return value is set at -0.31. Equity return is now at value -35.22, with -32.40 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.76. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -55.78.
Currently, EBITDA for the company is -172.84 million with net debt to EBITDA at 1.33. When we switch over and look at the enterprise to sales, we see a ratio of 4634.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.27.
Conclusion
In conclusion, Akero Therapeutics Inc (AKRO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
